 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1994 | Volume 121 Issue 2 | Pages 81-89
Objective: To determine the most effective and safe dose of enoxaparin to prevent deep venous thrombosis in high-risk surgical patients.
Design: A double-blind, randomized, multicenter clinical trial.
Setting: Private, university, and government hospitals in the United States.
Patients: 572 patients having elective hip replacement surgery, 568 of whom received study medication and had efficacy data available for evaluation.
Interventions: Patients were randomly assigned to one of three subcutaneous enoxaparin regimens: 10 mg once daily (161 patients); 40 mg once daily (199 patients); and 30 mg every 12 hours (208 patients). Treatment was initiated within 24 hours after surgery and continued for as long as 7 days. Treatment with 10 mg enoxaparin once daily was discontinued prematurely after an interim analysis showed an increased deep venous thrombosis incidence in this treatment group.
Measurements: Efficacy was determined by bilateral lower extremity venography, noninvasive vascular imaging methods, or clinical evidence on day 7 of treatment or earlier if clinically indicated.
Results: Deep venous thrombosis occurred in 25% (40 of 161) of the patients who received 10 mg of enoxaparin once daily; in 14% (27 of 199) of those receiving 40 mg of enoxaparin once daily; and in 11% (22 of 208) in those receiving 30 mg of enoxaparin every 12 hours. The incidence of deep venous thrombosis was significantly higher in patients who received 10 mg of enoxaparin once daily compared with those who received 40 mg of enoxaparin once daily (P = 0.02) or those who received 30 mg of enoxaparin every 12 hours (P < 0.001). The difference between the patients who received 40 mg once daily and those who received 30 mg every 12 hours was not significant. Only two cases of pulmonary embolism were diagnosed, one in patients receiving 40 mg of enoxaparin and one in those receiving 10 mg once daily. The incidence of hemorrhagic complications differed significantly between patients who received 10 mg of enoxaparin once daily (5%, 8 of 161 patients) and those who received 30 mg of enoxaparin every 12 hours (13%, 26 of 208; P < 0.05).
Conclusions: After surgery, enoxaparin, 40 mg once daily or 30 mg every 12 hours, is more effective than a regimen of 10 mg once daily to prevent deep venous thrombosis in patients having elective hip replacement surgery. The regimens of 40 mg once daily and 30 mg every 12 hours provided prophylaxis similar to the most effective drug treatments previously reported. The incidence of hemorrhagic episodes with the regimens of 40 mg once daily and 30 mg twice daily was higher than that observed with 10 mg once daily; however, major hemorrhage occurred in only 4% to 5% of patients receiving the higher-dose regimens. The risk-to-benefit ratio supports the use of enoxaparin as a therapeutic agent to prevent deep venous thrombosis in these patients.
*For a list of investigators, see the Appendix
ARTICLE
Efficacy and Safety of Enoxaparin to Prevent Deep Venous Thrombosis after Hip Replacement Surgery
This article has been cited by other articles:
 |
|
 |
|
  E. A Nutescu, R. K Lewis, J. M Finley, and G. T Schumock Hospital Guidelines for Use of Low-Molecular-Weight Heparins Ann. Pharmacother., July 1, 2003; 37(7): 1072 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Strebel, M. Prins, G. Agnelli, and H. R. Buller Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery? Arch Intern Med, July 8, 2002; 162(13): 1451 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Douketis, J. W. Eikelboom, D. J. Quinlan, A. R. Willan, and M. A. Crowther Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement: A Meta-analysis of Prospective Studies Investigating Symptomatic Outcomes Arch Intern Med, July 8, 2002; 162(13): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Sculco, C. W. Colwell Jr., V. D. Pellegrini Jr., G. H. Westrich, and F. Bottner Prophylaxis Against Venous Thromboembolic Disease in Patients Having a Total Hip or Knee Arthroplasty J. Bone Joint Surg. Am., March 1, 2002; 84(3): 466 - 477. [Full Text]
|
|
|
|
 |
|
 R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, M. Butcher, R. F. Brant, W. A. Ghali, D. Bergqvist, et al. Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty: A Systematic Review Ann Intern Med, November 20, 2001; 135(10): 858 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, W. A. Ghali, M. S. Butcher, R. F. Brant, D. Bergqvist, et al. Timing of Initial Administration of Low-Molecular-Weight Heparin Prophylaxis Against Deep Vein Thrombosis in Patients Following Elective Hip Arthroplasty: A Systematic Review Arch Intern Med, September 10, 2001; 161(16): 1952 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21 (7): e9 - e9. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Circulation, June 19, 2001; 103(24): 2994 - 3018. [Full Text] [PDF]
|
|
|
|
|
|
P. C. Comp, T. E. Spiro, R. J. Friedman, T. L. Whitsett, G. J. Johnson, G. A. Gardiner, G. C. Landon, and M. Jové Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement J. Bone Joint Surg. Am., March 1, 2001; 83(3): 336 - 336. [Abstract] [Full Text]
|
|
|
|
|
|
G. Merli, T. E. Spiro, C.-G. Olsson, U. Abildgaard, B. L. Davidson, A. Eldor, D. Elias, A. Grigg, D. Musset, G. M. Rodgers, et al. Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease Ann Intern Med, February 6, 2001; 134(3): 191 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF]
|
|
|
|
|
|
W. H. Geerts, J. A. Heit, G. P. Clagett, G. F. Pineo, C. W. Colwell, F. A. Anderson Jr., and H. B. Wheeler Prevention of Venous Thromboembolism Chest, January 1, 2001; 119(1_suppl): 132S - 175S. [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hull, G. F. Pineo, C. Francis, D. Bergqvist, C. Fellenius, K. Soderberg, A. Holmqvist, M. Mant, R. Dear, B. Baylis, et al. Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison Arch Intern Med, July 24, 2000; 160(14): 2199 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hull, G. F. Pineo, C. Francis, D. Bergqvist, C. Fellenius, K. Soderberg, A. Holmqvist, M. Mant, R. Dear, B. Baylis, et al. Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison Arch Intern Med, July 24, 2000; 160(14): 2208 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. SALVATI, V. D. PELLEGRINI, N. E. SHARROCK, P. A. LOTKE, D. W. MURRAY, H. POTTER, and G. H. WESTRICH Symposium - Recent Advances in Venous Thromboembolic Prophylaxis During and After Total Hip Replacement J. Bone Joint Surg. Am., February 1, 2000; 82(2): 252 - 70. [Full Text]
|
|
|
|
|
|
R. D. Hull, R. F. Brant, G. F. Pineo, P. D. Stein, G. E. Raskob, and K. A. Valentine Preoperative vs Postoperative Initiation of Low-Molecular-Weight Heparin Prophylaxis Against Venous Thromboembolism in Patients Undergoing Elective Hip Replacement Arch Intern Med, January 25, 1999; 159(2): 137 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Leclerc, M. Gent, J. Hirsh, W. H. Geerts, J. S. Ginsberg, and for the Canadian Collaborative Group The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With Enoxaparin: A Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty Arch Intern Med, April 27, 1998; 158(8): 873 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Robb and B. I. Eriksson Recombinant Hirudin Compared with Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement N. Engl. J. Med., March 26, 1998; 338(13): 920 - 921. [Full Text]
|
|
|
|
 |
|
 G. Agnelli Postdischarge prophylaxis for venous thromboembolism among high-risk surgery patients Vascular Medicine, February 1, 1998; 3(1): 51 - 56. [Abstract] [PDF]
|
|
|
|
|
|
J. I. Weitz Low-Molecular-Weight Heparins N. Engl. J. Med., September 4, 1997; 337(10): 688 - 699. [Full Text] [PDF]
|
|
|
|
|
|
C. W. FRANCIS, V. D. PELLEGRINI JR., S. TOTTERMAN, A. D. BOYD JR., V. J. MARDER, K. M. LIEBERT, B. N. STULBERG, D. C. AYERS, A. ROSENBERG, C. KESSLER, et al. Prevention of Deep-Vein Thrombosis after Total Hip Arthroplasty. Comparison of Warfarin and Dalteparin J. Bone Joint Surg. Am., September 1, 1997; 79(9): 1365 - 72. [Abstract] [Full Text]
|
|
|
|
|
|
M. Cohen, C. Demers, E. P. Gurfinkel, A. G.G. Turpie, G. J. Fromell, S. Goodman, A. Langer, R. M. Califf, K. A.A. Fox, J. Premmereur, et al. A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease N. Engl. J. Med., August 14, 1997; 337(7): 447 - 452. [Abstract] [Full Text] [PDF]
|
|
Article
